INTAGLIP OD 100 10 S

About

Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor specifically designed for the management of type 2 diabetes mellitus. Its primary mechanism involves the selective inhibition of the DPP-4 enzyme, which is responsible for the rapid inactivation of endogenous incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing this degradation, sitagliptin elevates the active concentrations of these incretins, leading to enhanced glucose-dependent insulin secretion from the pancreatic beta cells and a concomitant reduction in glucagon secretion from the pancreatic alpha cells. This results in improved glycemic control by lowering both fasting and postprandial blood glucose levels. The once-daily extended-release formulation ensures sustained therapeutic effects, making it a convenient and effective option as an adjunct to diet and exercise.

Uses

• Treatment of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• Used alone or in combination with other antidiabetic agents.
• To improve HbA1c levels in adults.

Directions For Use

Take one tablet of Sitagliptin 100mg orally once daily, with or without food, as directed by your physician.

Benefits

• Provides effective blood glucose reduction.
• Convenient once-daily dosing.
• Low risk of weight gain.
• Minimal risk of hypoglycemia when used as monotherapy.
• Improves both fasting and post-meal glucose levels.
• Generally well-tolerated with a favorable safety profile.

Side Effects

• Nasopharyngitis
• Headache
• Upper respiratory tract infection
• Diarrhea
• Nausea
• Abdominal discomfort
• Joint pain
• Back pain
• Peripheral edema
• Hypoglycemia (when combined with sulfonylureas or insulin)
• Pancreatitis (rare)
• Allergic reactions (rare)

Safety Measures

• Alcohol - Moderate alcohol intake is generally permissible, but patients should monitor blood glucose levels closely as alcohol can affect them.
• Pregnancy - Insufficient data on human pregnancy. Should be used only if the potential benefit outweighs the potential risk to the fetus.
• Breastfeeding - It is not known whether Sitagliptin is excreted in human milk. Caution should be exercised when administered to a nursing mother.
• Liver - No dose adjustment is typically needed for mild to moderate hepatic impairment. Use with caution in severe liver disease.
• Kidney - Dose adjustment is required for patients with moderate to severe renal impairment and end-stage renal disease.
• Lung - No specific concerns regarding lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.